MED-EL Acquires Two Gene Therapy Programs from Rescue Hearing, Targeting MYO7A and STRC Mutations for Hearing and Balance Disorders
核心洞察
MED-EL Elektromedizinische Geräte GmbH (搜索) has acquired two gene therapy programs from Rescue Hearing Inc. (搜索), targeting genetic hearing loss (搜索) and balance disorders caused by MYO7A (搜索) and STRC (搜索) gene mutations.
The STRC (搜索) program addresses a genetic cause of hearing disorders in a patient population currently managed primarily with hearing aids, while the MYO7A (搜索) program targets genetic balance disorders (搜索).
Dr. Hinrich Staecker, an early translational pioneer in inner ear gene therapy, will serve as Chief Scientist to advance the development of both programs.
INNSBRUCK, Austria — MED-EL Elektromedizinische Geräte GmbH (搜索), a global leader in hearing implant solutions, announced on June 30, 2026, the acquisition of two gene therapy programs from Rescue Hearing Inc. (搜索), marking the company's strategic entry into gene-based therapeutic approaches for inner ear disorders. The programs target genetic conditions associated with mutations in the MYO7A (搜索) and STRC (搜索) genes, addressing both balance and hearing dysfunction at their underlying biological source.
The MYO7A (搜索) gene therapy program is being developed to address a genetic cause of balance disorders, while the STRC (搜索) gene therapy program targets a genetic cause of hearing disorders, particularly in a patient population that is currently managed primarily with hearing aids. Both programs focus on the underlying biological mechanisms contributing to vestibular and auditory dysfunction.
"This acquisition represents a strategic step in MED-EL's mission to provide comprehensive hearing and balance solutions across the full continuum of care," said Dr. Ingeborg Hochmair, CEO of MED-EL. "By adding these gene therapy programs to our pipeline, we are exploring innovative approaches that may address the underlying genetic causes of certain disorders, while continuing to advance and invest in our proven hearing implant technologies."
A Complementary Strategy, Not a Replacement
MED-EL emphasized that these gene therapy programs are intended to augment, not replace, its core technologies. The acquisition reflects a broader strategy to address hearing and balance disorders through a range of complementary medical solutions. With this move, MED-EL expands its research and development activities into gene-based therapeutic approaches that complement the company's established portfolio of implantable and non-implantable hearing solutions.
Dr. Hinrich Staecker, described as an early translational pioneer in gene therapy in the inner ear, will serve as Chief Scientist for advancing the development of the two programs. "Targeting the genetic basis of inner ear disorders offers the potential to address disease mechanisms at their source," Dr. Staecker said. "The MYO7A (搜索) and STRC (搜索) programs represent important steps in translating scientific insights into potential therapeutic approaches, complementing existing clinical solutions."
Transaction Details and Future Cooperation
Under the terms of the agreement, MED-EL has acquired full rights to further develop, advance, and potentially commercialize the two programs. Financial terms of the transaction were not disclosed. Rescue Hearing Inc. (搜索), a biotechnology company focused on the development of genetic therapies for hearing and balance disorders, developed the MYO7A (搜索) and STRC (搜索) programs in line with their genetic interventions for inner ear disorders.
"MED-EL's established expertise in hearing science and clinical application makes the company a strong steward for these programs," said Jim Ayala, CEO of Rescue Hearing Inc. (搜索) "We are pleased to see them become part of a broader portfolio aimed at improving outcomes for people with hearing and balance disorders."
Both companies have indicated that they will continue their cooperation following the acquisition.